Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm; Nigel Armstrong; Bram L. T. Ramaekers; Xavier Pouwels; Shona Lang; Svenja Petersohn; Rob Riemsma; Gillian Worthy; Lisa Stirk; Janine Ross; Jos Kleijnen; Manuela A. Joore

doi:10.1007/s40273-018-0723-5

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm^*, Nigel Armstrong, Bram L. T. Ramaekers, Xavier Pouwels, Shona Lang, Svenja Petersohn, Rob Riemsma, Gillian Worthy, Lisa Stirk, Janine Ross, Jos Kleijnen, Manuela A. Joore

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

4 Citations (Web of Science)

Original language	English
Pages (from-to)	655-667
Number of pages	13
Journal	Pharmacoeconomics
Volume	37
Issue number	5
DOIs	https://doi.org/10.1007/s40273-018-0723-5
Publication status	Published - May 2019

Keywords

PHASE-III TRIAL
WEEKLY PACLITAXEL
VINFLUNINE PLUS
SUPPORTIVE CARE
OPEN-LABEL
CARCINOMA
MONOTHERAPY
MULTICENTER
DOCETAXEL

Access to Document

10.1007/s40273-018-0723-5

Cite this

Grimm, S. E., Armstrong, N., Ramaekers, B. L. T., Pouwels, X., Lang, S., Petersohn, S., Riemsma, R., Worthy, G., Stirk, L., Ross, J., Kleijnen, J., & Joore, M. A. (2019). Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 37(5), 655-667. https://doi.org/10.1007/s40273-018-0723-5

Grimm, Sabine E. ; Armstrong, Nigel ; Ramaekers, Bram L. T. ; Pouwels, Xavier ; Lang, Shona ; Petersohn, Svenja ; Riemsma, Rob ; Worthy, Gillian ; Stirk, Lisa ; Ross, Janine ; Kleijnen, Jos ; Joore, Manuela A. / Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. In: Pharmacoeconomics. 2019 ; Vol. 37, No. 5. pp. 655-667.

@article{3bc576bbf4d54c149801df0163bbee76,

title = "Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

keywords = "PHASE-III TRIAL, WEEKLY PACLITAXEL, VINFLUNINE PLUS, SUPPORTIVE CARE, OPEN-LABEL, CARCINOMA, MONOTHERAPY, MULTICENTER, DOCETAXEL",

author = "Grimm, {Sabine E.} and Nigel Armstrong and Ramaekers, {Bram L. T.} and Xavier Pouwels and Shona Lang and Svenja Petersohn and Rob Riemsma and Gillian Worthy and Lisa Stirk and Janine Ross and Jos Kleijnen and Joore, {Manuela A.}",

year = "2019",

month = may,

doi = "10.1007/s40273-018-0723-5",

language = "English",

volume = "37",

pages = "655--667",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "5",

}

Grimm, SE, Armstrong, N, Ramaekers, BLT, Pouwels, X, Lang, S, Petersohn, S, Riemsma, R, Worthy, G, Stirk, L, Ross, J, Kleijnen, J & Joore, MA 2019, 'Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics, vol. 37, no. 5, pp. 655-667. https://doi.org/10.1007/s40273-018-0723-5

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Grimm, Sabine E.; Armstrong, Nigel; Ramaekers, Bram L. T.; Pouwels, Xavier; Lang, Shona; Petersohn, Svenja; Riemsma, Rob; Worthy, Gillian; Stirk, Lisa; Ross, Janine; Kleijnen, Jos; Joore, Manuela A.

In: Pharmacoeconomics, Vol. 37, No. 5, 05.2019, p. 655-667.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer

T2 - An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Grimm, Sabine E.

AU - Armstrong, Nigel

AU - Ramaekers, Bram L. T.

AU - Pouwels, Xavier

AU - Lang, Shona

AU - Petersohn, Svenja

AU - Riemsma, Rob

AU - Worthy, Gillian

AU - Stirk, Lisa

AU - Ross, Janine

AU - Kleijnen, Jos

AU - Joore, Manuela A.

PY - 2019/5

Y1 - 2019/5

KW - PHASE-III TRIAL

KW - WEEKLY PACLITAXEL

KW - VINFLUNINE PLUS

KW - SUPPORTIVE CARE

KW - OPEN-LABEL

KW - CARCINOMA

KW - MONOTHERAPY

KW - MULTICENTER

KW - DOCETAXEL

U2 - 10.1007/s40273-018-0723-5

DO - 10.1007/s40273-018-0723-5

M3 - Review article

C2 - 30293207

VL - 37

SP - 655

EP - 667

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 5

ER -